Clinical Trials

NCT Number: NCT06318273 Phase: PHASE1 Trial Summary: Prostate cancer has the second highest incidence rate and is the fifth leading cause of cancer-related deaths among men worldwide. The purpose of this study is to assess safety, pharmacokinetics, and – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): AbbVie Acronym:

NCT Number: NCT06334432 Phase: PHASE1|PHASE2 Trial Summary: NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Nuvation Bio Inc. Acronym:

NCT Number: NCT06056791 Phase: PHASE1|PHASE2 Trial Summary: This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart. The st – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Inmune Bio, Inc. Acronym: CaRe

NCT Number: NCT06064149 Phase: NA Trial Summary: The overarching goal of this trial is to develop mechanisms to improve cardiovascular care among such prostate cancer patients receiving ADT by increasing patient awareness of individualized cardiovas – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Vivek Narayan Acronym:

NCT Number: NCT06074510 Phase: PHASE4 Trial Summary: The purpose of this study is to learn whether PYLARIFY PET imaging (study scan) can safely and accurately detect the presence or absence of prostate cancer growing beyond the prostate gland in men wit – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Lantheus Medical Imaging Acronym: […]

NCT Number: NCT06085729 Phase: PHASE1|PHASE2 Trial Summary: To find the best dose of ADI-PEG20 that can be given in combination with carboplatin and cabazitaxel to patients with AVPC. – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

NCT Number: NCT06111781 Phase: PHASE2 Trial Summary: The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereo – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Yale University Acronym:

NCT Number: NCT06193486 Phase: PHASE1 Trial Summary: This is a phase 1 single center clinical trial for patients with end stage Metastatic Castration Resistant Prostate Cancer who have progressed through standard of care treatment options and are on zol – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): H. Lee Moffitt Cancer Center and […]

NCT Number: NCT06237179 Phase: PHASE1|PHASE2 Trial Summary: To test the preliminary effectiveness of a home-based exercise training (ET) intervention to improve exercise capacity (VO2 peak & 6-minute walk distance [6MWD]) among prostate cancer (PC) patients – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Virginia Commonwealth University Acronym: EXTRA-PC

NCT Number: NCT06238479 Phase: PHASE1 Trial Summary: The purpose of this study is to find out whether the study drug, LY4101174, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors. The study is conducted in two pa – see clinicaltrials.gov for information and location Clinicaltrials.gov Trial Sponsor(s): Eli Lilly and Company […]